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Abstract
46,XY differences and/or disorders of sex development (DSD) are clinically and 
genetically heterogeneous conditions. Although complete androgen insensitivity 
syndrome has a strong genotype–phenotype correlation, the other types of 46,XY DSD 
are less well defined, and thus, the precise diagnosis is challenging. This study focused 
on comparing the relationship between clinical assessment and genetic findings in 
a cohort of well-phenotyped patients with 46,XY DSD. The study was an analysis of 
clinical investigations followed by genetic testing performed on 35 patients presenting 
to a single center. The clinical assessment included external masculinization score 
(EMS), endocrine profiling and radiological evaluation. Array-comparative genomic 
hybridization (array-CGH) and sequencing of DSD-related genes were performed. Using 
an integrated approach, reaching the definitive diagnosis was possible in 12 children. 
The correlation between clinical and genetic findings was higher in patients with a 
more severe phenotype (median EMS 2.5 vs 6; P = 0.04). However, in 13 children, at least 
one variant of uncertain significance was identified, and most times this variant did 
not correspond to the original clinical diagnosis. In three patients, the genetic studies 
guided further clinical assessment which resulted in a reclassification of initial clinical 
diagnosis. Furthermore, we identified eight patients harboring variants in more than 
one DSD genes, which was not seen in controls (2.5%; P = 0.0003). In summary, taking 
into account potential challenges in reaching the definitive diagnosis in 46,XY DSD, only 
integrated approach seems to be the best routine practice.
Introduction
Differences and/or disorders of sex development (DSD) 
represent rare congenital conditions in which gonadal, 
chromosomal or anatomical sex is atypical. Due to 
its heterogeneous clinical presentation and genetic 
architecture, achieving a definitive diagnosis is challenging, 
especially when associated with 46,XY karyotype (1). 
Indeed, with the exception of several conditions with well-
defined phenotypes that point to a specific underlying 
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genetic cause, i.e. complete androgen insensitivity 
(CAIS) (2), in the majority of cases neither the clinical 
presentation nor the phenotype–genotype correlation is 
indicative enough to predict a precise diagnosis.
The observed phenotypic heterogeneity is partially 
explained by complex mechanisms that control male sex 
development, and when disturbed may result in disorder 
of gonadal development (DGD), disorder of androgen 
synthesis (DAS) or disorder of androgen action (DAA) 
(1). Similar to the diverse pathophysiology, the genetic 
background varies with more than 40 genes having 
been implicated in its pathogenicity and associated with 
different modes of inheritance including autosomal 
dominant, autosomal recessive, X-linked and de novo 
(1). Moreover, some DSD conditions may result from 
copy number variations (CNVs), especially in cases with 
gonadal dysgenesis or in the presence of associated 
malformations (3, 4, 5). In addition, recent findings (6, 
7, 8) indicate oligogenicity, defined as mutation in more 
than one gene, as a possible mode of inheritance in DSD.
Therefore, in the light of phenotypic variability and 
the multiple genes associated with the phenotype, the 
introduction of next-generation sequencing (NGS) methods 
into the field of DSD significantly improved the diagnostic 
yield (6, 9). While whole-exome and/or genome sequencing 
(WES/WGS) are still reserved for the research environment, 
targeted gene panels are becoming widely used in the 
diagnostic algorithms of 46,XY DSD on a routine basis (10). 
However, as their utility was mostly proven in research 
genetic centers, there are still missing data regarding its 
application in a clinical setting, where reporting the genetic 
result to the patient and their family might be complicated 
by low sensitivity and/or specificity of endocrine tests that 
are unable to fully define the phenotype (11), potentially 
inconclusive results with the identification of a variant of 
uncertain significance or the increasingly stronger argument 
for oligogenicity as a possible mode of inheritance. This 
study aimed to compare the relationship between the clinical 
diagnosis (based on physical examination, biochemical and 
radiological assessment) to the result of genetic assessment 
using array-comparative genomic hybridization (array-
CGH) and sequencing 37 genes known to underlie 46,XY 
DSD in a cohort of 35 patients.
Material and methods
Study group
The study group initially consisted of 36 patients 
(34 probands) diagnosed with 46,XY DSD who were referred 
to a multidisciplinary clinic at a single pediatric endocrinology 
department for further investigations. Patients presented 
with either atypical genitalia in infants and children 
or atypical sexual development in adolescents. The 
appearance of external genitalia was described using the 
external masculinization score (EMS) (12), and consistent 
with UK guidance (13), only those with an EMS less than 
11 were included. During the routine genetic testing 
prior to this study, one patient with complete gonadal 
dysgenesis was found to harbor a causative mutation 
in the SRY gene, and therefore, was excluded from the 
present study. Among 35 patients, 21 were raised as boys, 
while the remaining 14 were raised as girls. The cohort was 
classified according to above mentioned guidelines (13), 
with an exception of a diagnosis of a non-specific disorder 
of undermasculinization (NSDUM) assigned to those boys 
with normal testicular function before the analysis of the 
AR gene (14), and a diagnosis of syndromic 46,XY DSD 
assigned to those with multiple (>1) associated conditions. 
The definition of small for gestational age (SGA) was a 
birth weight less than the tenth centile.
The study was approved by the Poznan University of 
Medical Sciences Medical Ethical Committee (Registration 
number 505/13) and informed consent was obtained from 
all participants.
Endocrine investigations
Standard hormonal measurements were performed 
using commercial kits. Luteinizing hormone (LH), 
follicle-stimulating hormone (FSH) and estradiol (E2) 
were assessed using chemiluminescent microparticle 
immunoassay (CMIA) by Architect (Abbott Laboratories) 
and dihydrotestosterone (DHT) by DHT-optimized 
ELISA (DRG Instruments GmbH, Germany). 
Androstenedione (A) and testosterone were measured 
by radioimmunoassays: Active Androstenedione RIA 
(Beckman Coulter, Immunotech) and TESTO-RIA-CT 
(DIAsource ImmunoAssays S.A., Belgium), respectively. 
Anti-Müllerian hormone (AMH) and inhibin B were 
evaluated by ELx800 Absorbance Microplate Reader (Bio-
Tek Instruments) using Gen II ELISA assay (Beckman 
Coulter, Diagnostic Systems Laboratories, Inc.). The 
protocol for the hCG test was based on the administration 
of 1000 IU of hCG (Pregnyl) intramuscularly for three 
consecutive days with blood drawn immediately prior 
to the test on day one and 24 h after the last injection. 
An adequate increase of testosterone after hCG was 
considered to be sufficient if testosterone was over 
3.5 (nmol/L) (15). Testosterone/DHT ratio was recognized 
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as elevated if over 25 (16), while testosterone/A ratio was 
considered as decreased if below 0.8 (17). The GnRH test 
was conducting using an intravenous administration of 
2.5 µg of gonadorelinum (Relefact LH-RH) per kilogram 
(max. 100 µg) with a blood drawn prior to the test and 
at 30 min and at 60 min after injection. The assessment 
of internal genitalia (presence or absence of uterus, 
localization of undescended gonads) was performed using 
transabdominal ultrasound examination.
Genetic investigations
After a thorough literature and database search (OMIM, 
HGMD and ClinVar), a list of 37 genes implicated in 
46,XY DSD and included in the TruSight One sequencing 
kit (Illumina) were selected for evaluation (Table  1). If 
the gene was only reported in a single human case or 
family, then strong supporting in vitro or in vivo data 
must also be present for the gene to be included (CBX2, 
FGFR2, WWOX, and TSPY1) as stated in ‘Guidelines for 
investigating causality of sequence variants in human 
disease’ (18). Following other studies on the genetic 
etiology of 46,XY DSD (6, 7), we also evaluated a list of 
21 genes implicated in congenital hypogonadotropic 
hypogonadism (CHH) (Supplementary Table 1, see section 
on supplementary data given at the end of this article), 
a condition that shares some clinical presentations with 
DSD (i.e. cryptorchidism or micropenis) to further study 
their contribution. Reference transcript numbers for all 
genes evaluated are noted in Supplementary Table 2.
Blood samples were collected and frozen at −20°C until 
the analysis, and molecular studies were performed on 
genomic DNA isolated from peripheral blood leukocytes 
using FlexiGene DNA Kit (QIAGEN).
Array-CGH was performed using a custom whole 
genome 180 K oligonucleotide array (Sure Print G3 
Human 4x180K) manufactured by Agilent Technologies. 
The median probe spacing for the arrays was 11 kb. 
Digestion, labeling and hybridization were completed 
according to manufacturer’s protocols. Scanning and 
image analysis were performed as per oligonucleotide 
array-CGH protocol (Agilent, version 4.0). Microarrays 
were scanned using the Agilent Scanner. Agilent 
CytoGenomics Analytics software (v4.0.3.12) was used to 
visualize, detect and analyze the CNVs from microarray 
profiles using Tiff images from data. Identified CNVs were 
cross-checked with data gathered from the following 
databases: DGV (Database of Genomic Variants) (http://
dgv.tcag.ca/dgv/app/home), ISCA (International Standard 
for Cytogenomic Arrays) (http://dbsearch.clinicalgenome.
org/search), NCBI (National Center for Biotechnology 
Information) (https://ncbi.nlm.nih.gov), as well as a local 
database of CNV.
For sequencing of the 37 DSD-related genes, patients' 
DNA samples were normalized to 5 ng/µL in 10 µL of 
Tris–HCl 10 mM pH 8.5 (total DNA mass 50 ng). Libraries 
were constructed for NGS using the TruSight One 
Sequencing Panel Kit (Illumina, Inc.) according to the 
manufacturer’s protocol, and 150 basepair paired-end 
reads were generated on the MiSeq instrument (Illumina). 
Sample runs were validated as successful if the sequencing 
run yield was >7.5 Gb, had >96% of reads aligning to 
the human genome and had an overall 30× coverage of 
>95%. Each run included 3 samples. Only variants with 
a read depth coverage of >10× and a quality score of >95 
passed quality control. Given these stringent parameters 
for genotype calls, Sanger sequencing was not required for 
further confirmation (19).
The raw data (fastq files) from the MiSeq sequencing 
of the TruSight One libraries were uploaded to Saphetor 
(www.saphetor.com, Lausanne, Switzerland); however, a 
mask was applied to the data such that only the 37 DSD-
related genes were analyzed. This analysis consisted of 
read alignments, basepair calling and annotation with 
HGVS (Human Genome Variation Society) nomenclature, 
function and conservation. Splice-junction (±6 base 
pairs) and non-synonymous variants with a minor allele 
frequency (MAF) <1% in Genome Aggregation Database 
(GnomAd) were evaluated. Of note, a missense variant 
was considered to be damaging if it was predicted to 
be damaging by one of the two in silico predictive 
algorithms, SIFT and/or MutationTaster. The variants were 
classified into five categories according to the American 
College of Medical Genetics (ACMG) guidelines (20) 
using the InterVar program (http://wintervar.wglab.org/): 
pathogenic, likely pathogenic and variants of uncertain 
significance (VUS), likely benign, and benign. Variants 
classified as benign or likely benign were not included in 
this study. Additionally, as previously described (6), any 
expansions in the first exon of the AR gene of CAG over 
27 repeats (21) or CGG over 24 repeats (22) were classified 
as VUS, as their contribution into DSD phenotype is still 
uncertain. A definitive (genetically confirmed) diagnosis 
was considered to be achieved when pathogenic or likely 
pathogenic variants were identified.
Oligogenicity of the DSD cohort was assessed against 
the ‘Cohorte Lausannoise’ (CoLaus) control population, 
consisting of 405 participants of mixed European 
origin, phenotyped as described by Firmann et  al., in 
whom whole exome sequencing was performed (23). 
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Consistent with the DSD cases in the study, only genotype 
calls with read depths >10× and quality scores >95 were 
used. Additionally, the 37 DSD-related genes were covered 
in both the whole exome data of the CoLaus cohort 
and the TruSight One Sequencing Panel Kit of the DSD 
cohort to an average read depth of >20× for >99% of the 
nucleotides in the genes.
Case vs control statistical analysis for an enrichment 
of individual variants or oligogenicity was performed 
using a two-tailed Fisher’s exact test. The Mann–Whitney 
U test was performed to assess the difference in EMS in 
cases reaching the definitive diagnosis vs cases with no 
final diagnosis. A statistic of P < 0.05 was considered to be 
significant.
Table 1 46,XY DSD-related genes (37 genes).
Gene Phenotype Inheritance Location OMIM
Disorder of gonadal development (DGD)
 ARX X-linked lissencephaly with abnormal genitalia XL Xp21.3 300382
 ATRX Alpha thalassemia X-linked intellectual 
disability syndrome
XL Xq21.1 300032
 CBX2 CGD AR 17q25.3 602770
 DHH CGD or PGD with or without polyneuropathy AR 12q13.12 605423
 DMRT1 CGD or PGD with dysmorphic features (9p 
monosomy syndrome)
AD, deletion 9p24.3 602424
 FGFR2 CGD with craniosynostosis AD 10q26.13 176943
 GATA4 PGD with or without congenital heart defect AD 8p23.1 600576
 MAP3K1 CGD; PGD AD 5q11.2 613762
 NR0B1 CGD; PGD XL, duplication Xp21.2 300473
 NR5A1 CGD; PGD; TRS; hypospadias; cryptorchidism AR; AD 9q33.3 184757
 SOX9 CGD or PGD with campomelic and acampomelic 
dysplasia
AD 17q24.3 608160
 SRY CGD; PGD YL Yp11.2 480000
 TSPYL1 PGD and sudden infant death AR 6q22.1 604714
 WNT4 Ovotesticular DSD; CGD (duplication) AD, duplication 1p36.12 603490
 WT1 CGD or PGD within Denysh Drash or Frasier 
syndrome ; TRS; hypospadias
AD 11p13 607102
 WWOX PGD AD, deletion 16q23.2
 ZFPM2 CGD; PGD AD 8q23.1 603693
Disorder of androgen synthesis (DAS)
 AKR1C2 3α-hydroxysteroid dehydrogenase deficiency AR 10p15.1 600450
 AKR1C4 3α-hydroxysteroid dehydrogenase deficiency AR 10p15.1 600451
 CYB5A Cytochrome b5 deficiency AR 18q22.3 250790
 CYP11A1 P450 side chain cleavage syndrome AR 15q24.1 118485
 CYP17A1 Combined 17-hydroxylase, 17,20-lyase 
deficiency 
AR 10q24.32 609300
 HSD3B2 3β-hydroxysteroid dehydrogenase II deficiency AR 1p12 613890
 HSD17B3 17β-hydroxysteroid deficiency type 3 AR 9q22.32 605573
 LHCGR Leydig cell hypoplasia AR 2p16.3 152790
 POR P450 oxidoreductase deficiency AR 7q11.23 124015
 SRD5A2 5α-reductase deficiency AR 2p23.1 607306
 STAR Lipoid congenital adrenal hyperplasia AR 8p11.23 250790
Disorder of androgen action (DAA)
 AR CAIS; PAIS; hypospadias XL Xq12 313700
Other and syndromic forms of DSD (sDSD)
 AMH PMDS type 1 AR 19p13.3 600957
 AMHR2 PMDS type 2 AR 12q13.13 600956
 DHCR7 Smith-Lemli-Opitz syndrome AR 11q13.4 602858
 HOXA13 Hand-foot-genital syndrome AD 7q15.2 142959
 INSL3 Cryptorchidism AD 19p13.11 146738
 MAMLD1 CGD; PGD; hypospadias XL Xq28 300120
 MID1 Opitz GBBB syndrome XL Xp22.2 300552
 RXFP2 Cryptorchidism AD 13q13.1 606655
AR, autosomal recessive; CAIS, complete androgen insensitivity syndrome; CGD, complete gonadal dysgenesis; PAIS, partial androgen insensitivity 
syndrome; PGD, partial gonadal dysgenesis; PMDS, persistent Müllerian duct syndrome; TRS, testicular regression syndrome; TRS, testicular regression 
syndrome; XL, X-linked; YL, Y-linked.
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Results
Clinical approach based on physical and 
endocrine evaluation
After structured clinical assessment followed by 
thorough endocrine evaluation including biochemical 
and radiological tests, each case was attributed a clinical 
diagnosis. All data regarding phenotyping are provided 
in Supplementary Tables  3 and 4. The median EMS was 
4.5 (0–9). In all cases with low plasma level of testosterone 
(basal value if assessed during expected minipuberty/
puberty or after hCG test if assessed during childhood) 
and AMH, a subcategory of DGD was attributed. Among 
this subgroup, there were (i) five patients with testicular 
regression syndrome (TRS), as despite lack of testicles they 
presented with male external genitalia and no Müllerian 
structures were identified on the ultrasound and (ii) four 
patients with complete gonadal dysgenesis (CGD), as they 
presented with female external genitalia, high plasma 
gonadotropins and an infantile uterus. Additionally, for 
patients with low plasma level of testosterone or high 
testosterone/DHT ratio, an AMH serum level within normal 
ranges, and no Müllerian structures, a subcategory of DAS 
(disorder of androgen synthesis) was established. Namely, 
there were three patients suspected for a 5α-reductase 
deficiency (5αRD) and one patient with undetectable 
testosterone plasma level and no uterus on the ultrasound 
indicating proper level of AMH during fetal life. In addition, 
a subcategory of disorder of androgen action (DAA) was 
attributed to those with proper gonadal function reflected 
by normal to high plasma levels of testosterone and AMH 
and no Müllerian structures. Namely, six patients with 
atypical genitalia received a phenotypic diagnosis of 
NSDUM, and eight patients were diagnosed with either 
a complete or partial form of androgen insensitivity 
syndrome (CAIS or PAIS) depending on the appearance 
of the external genitalia. Lastly, there were eight children 
that received a phenotypic diagnosis of syndromic DSD, 
as they presented with multiple associated conditions 
(i.e.: psychomotor delay, dysmorphic features, congenital 
heart defect). Additionally, although the majority of 
children presented with normal adrenal function, there 
were two syndromic patients with a primary (ID 32) 
and a secondary adrenal insufficiency (ID 30). (Fig.  1, 
Supplementary Tables 3 and 4).
Array-CGH
Given the incidence of genomic rearrangements in patients 
with DGD and syndromic forms of DSD, array-CGH 
was first performed on 10 of the 17 patients with CGD, 
TRS or sDSD (Fig. 2). No pathogenic genomic structural 
abnormalities were identified in these patients.
Sequencing results and their relationship to 
clinical diagnosis
Sequencing of the 37 genes implicated in DSD was 
performed successfully in all 35 patients (Fig.  2). The 
results were filtered according to the strategy described 
in the methods, including ACMG variant classification. 
This analysis identified 11 pathogenic variants, 2 likely 
pathogenic variants and 17 VUS (Table 2). Interestingly, 
each patient harbored at least one variant in 15 out 
of the 37 DSD-related genes, and most frequently, 
these were missense mutations. There were recurrent 
mutations in the AR and HSD17B3 genes in unrelated 
patients (Table 2).
As a definitive genetic diagnosis was considered 
when pathogenic or likely pathogenic variants were 
identified, 12 cases were assigned a definitive genetic 
diagnosis. In the remaining patients, the final diagnosis 
remained at the clinical level, as either no variant 
was identified (n = 15) or at least one VUS was found 
(n = 8) (Fig.  3). In the majority of cases, the variant 
was classified as VUS primarily due to a discordance 
between the phenotype and genetic mutation or, in 
cases with expansion of the number of CAG repeats, 
due to undetermined significance of its contribution to 
the DSD phenotype. Overall, 13 patients were found to 
harbor at least one VUS.
Among those with a genetically confirmed diagnosis 
(n = 12), nine patients had a clinical and endocrine 
evaluation that enabled an accurate initial identification 
of the underlying genetic cause. Namely, in seven 
patients suspected for CAIS and one for NSDUM, the 
pathogenic variant was identified in the AR gene, as 
well as one case classified with DAS was found to harbor 
compound heterozygote variants in the HSD17B3 gene. 
However, in three patients, the result of the genetic 
assessment led to the re-evaluation of the initial 
clinical diagnosis which subsequently led to diagnostic 
reclassification. Specifically, in patients suspected for a 
disorder of androgen action (ID 14 and 27), variants in 
the WT1 and NR5A1 genes, respectively, were identified 
indicating a disorder of gonadal dysgenesis. Additionally, 
a patient initially classified with 5α-reductase deficiency 
(ID 11) was found to harbor a likely pathogenic variant 
in the HOXA13 gene implicated in syndromic forms 
of DSD.
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Factors correlating with achieving a definitive 
genetic diagnosis
Patients for whom a definitive genetic diagnosis was 
rendered had a significantly lower mean EMS score (i.e. 
had a more severe phenotype), than patients with either 
a VUS or with no variant (2.5 vs 6, P = 0.04). Additionally, 
the highest genetic diagnostic yield was seen in cases 
initially suspected of DAA (10 patients out of 14), followed 
by patients classified as DAS (two patients out of four). 
However, a final genetic diagnosis was not possible in any 
of the patients suspected of DGD or sDSD.
Oligogenic inheritance in DSD patients
There were eight patients (23%) harboring a mutation in 
more than one DSD gene (Table 2). To evaluate whether the 
DSD cohort was statistically enriched for oligogenicity, we 
compared the results to exome sequencing data from the 
247 male participants in the ‘Cohorte Lausannoise’ CoLaus 
control population. As ACMG criteria are not intended 
for use in non-monogenic disorders (20), variants in 
37 DSD-related genes were filtered for non-synonymous 
variants with a MAF <1.0%, including nonsense, splice-
site (±6 base pairs) and missense variants found to be 
damaging in at least one of the two protein prediction 
programs, SIFT or MutationTaster. There was a statistical 
enrichment in oligogenic variants in our DSD cohort 
compared to CoLaus controls (23% vs 2.5%; P = 0.0003).
Variants in known CHH genes
Despite the fact that DSD patients typically do not present 
with hypogonadotropic hypogonadism, there is a small 
overlap in clinical presentation, namely the presence of 
micropenis and/or cryptorchidism. Therefore, several 
groups have previously explored a potential genetic 
overlap in these patients related to the known CHH 
genes (6, 7). Similarly, we evaluated our DSD cohort, 
within which four heterozygous and one hemizygous rare 
variants in the known CHH genes were identified in five 
DSD patients (14%) who actually presented with high 
gonadotrophin plasma level (Supplementary Tables  4 
and 5). There was no statistically significant difference 
Endocrine tests
(biochemical and
radiological)
7 boys and
1 girl with sDSD
6 boys with NSDUM
7 girls with CAIS
1 girl with PAIS
low T# 0.3± 0.4
low AMH# 0.4±0.4
+/- uterus
high T/DHT 40 ±10.7 
or low T 0
normal AMH 199.1±50.6 
no uterus
associated conditions
Clinical 
assessment
(EMS <11)
normal T 4.5±3.2
normal AMH ‡ 175.8 ±116
no uterus
sDSD (n=8)DGD (n=9) DAS (n=4) DAA (n=14)
5 boys with TRS
4 girls with CGD
3 boys with 5αRD
1 girl with DAS
35 children
with 46,XY DSD
Figure 1
Identified phenotypes based on clinical assessment and endocrine tests. AMH, anti-Müllerian hormone; CAIS, complete androgen insensitivity syndrome; 
CGD, complete gonadal dysgenesis; 5α-reductase deficiency; DAA, disorder of androgen action; DAS, disorder of androgen synthesis; DGD, disorder of 
gonadal development; DHT, dihydrotestosterone; DSD, disorder of sex development; EMS, external masculinization score; NSDUM, non-syndromic disorder 
of undermasculinization; PAIS, partial androgen insensitivity syndrome; sDSD, syndromic DSD; TRS, testicular regression syndrome; testosterone levels, if 
not assessed during minipuberty or puberty, were after hCG stimulation test if available; #(ng/mL); †for pubertal boys (n = 2) inhibin B level was considered.
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between the DSD cohort and the CoLaus controls (14% vs 
20%, P = 0.3) at the individual variant level, gene level or 
overall panel of genes.
Discussion
Despite the introduction of NGS methods into the 
clinical setting, the elucidation of genetic background 
in 46,XY DSD remains challenging. We presented the 
results on the integrated approach combining clinical 
and genetic evaluation of a cohort of 46,XY DSD patients 
systematically assessed in one center. This integrated 
approach resulted in identification of genetic findings 
in one-third of patients, while the final diagnosis in 
rest of them remained clinical only. As expected, a wide 
spectrum of phenotypes was observed leading to further 
subcategorization of the DSD cohort into DGD, DAS, DAA 
and sDSD. Thus, although the sample size was limited, the 
cohort appeared to be representative.
Importantly, the NGS of 37 DSD-related genes 
produced valuable results. The diagnostic yield (i.e. 
percentage of samples with pathogenic or likely pathogenic 
genetic results) in our cohort was 34% (12/35), which is 
comparable to other reports (24, 25). In the majority of 
patients with a definitive diagnosis (9/12), physical and 
endocrine evaluation was sensitive and/or specific enough 
to clearly identify the underlying genetic cause. However, 
with the exception of one case classified as DAS, this was 
only true for patients suspected of DAA – a condition 
with the strongest correlation between phenotype and 
genotype when presenting with a CAIS phenotype (2).
Given the variable specificity of endocrine tests 
to accurately diagnose a phenotype (i.e. androgens’ 
ratios in the diagnosis of DAS (11, 26, 27)) and since 
some conditions may present with a wide spectrum of 
phenotypes (i.e. phenotypes associated with genes such as 
NR5A1 (28) or WT1 (29)), an accurate diagnosis may only 
be possible with parallel genetic evaluation. Interestingly, 
the genetic results obtained in the present study lead to 
the re-evaluation of the clinical diagnosis in 3 patients, 
and the subsequent reclassification of their diagnosis. 
Specifically, one patient (ID 11) with distal limb anomalies, 
an abnormal testosterone/DHT ratio and initially 
suspected of 5αRD was finally accurately diagnosed with 
a hand-foot-genital syndrome after the identification of a 
pathogenic variant in the HOXA13 gene (30). Of note, a 
clinical diagnosis of suspected 5αRD was not genetically 
confirmed in any of the patients in our cohort, further 
confirming the limited utility of testosterone/DHT ratios 
in the diagnosis of 5α-reductase deficiency. Furthermore, 
two patients (ID 14 and 27) were initially suspected as 
having DAA, but were found to harbor likely pathogenic 
mutations in the WT1 and NR5A1 genes, respectively. It 
has been established that mutations in both genes are 
implicated in a broad spectrum of phenotypes. In the case 
of mutations in the WT1 gene, phenotypes can range from 
hypospadias (29, 31) to much more severe phenotypes 
such as WAGR (Wilms tumor, aniridia, genitourinary 
anomalies, and mental retardation), Frasier or Denys-
Drash syndromes (1, 29). Phenotypes for patients carrying 
mutations in the NR5A1 gene cover a spectrum of different 
degrees of gonadal dysgenesis, with or without associated 
adrenal insufficiency (28).
Figure 2
Genetic approach according to 
different DSD subcategories. 
array-CGH, array comparative 
genomic hybridization; DAA, 
disorder of androgen action; DAS, 
disorder of androgen synthesis; 
DGD, disorder of gonadal 
development; DSD, disorder of 
sex development; sDSD, 
syndromic DSD.
sDSDDGD DAS DAA
35 children
with 46,XY DSD
array-CGH array-CGH
Sequencing of DSD-related genes
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Our study showed that patients with a more severe 
phenotype (mean EMS score 2.5) were more likely to have 
a conclusive genetic diagnosis than those with less severe 
phenotypes (mean EMS score 6), P = 0.04. This lower 
diagnostic yield in children with a less severe phenotype 
is likely due to several reasons. Since it is difficult to 
definitively draw a line between the DSD and the mild 
and common urogenital defect such as hypospadias (14) 
that can be caused by environmental factors as well as 
genetic polymorphisms (31, 32), the enrollment of cases 
with signs of undermasculinization into the study group 
may have resulted in a bias. However, as it is known that 
the degree of undermasculinization reflected by lower EMS 
does not always increase the likelihood of a diagnostic 
yield (5, 33), it is debatable to exclude mild DSD cases 
from systematic assessment.
The diagnostic rate differed among DSD subcategories. 
The highest diagnostic rate (10 cases out of 14) was seen 
among suspected DAA patients, followed by the DAS 
subgroup (two cases out of four). Despite the small sample 
size, these findings are consistent with the results of a 
targeted gene study on the largest DSD cohort to date 
(6). However, in contrast with other report, no definitive 
genetic diagnosis was able to be rendered in patients 
with syndromic DSD or DGD. One of the reasons might 
have been the inclusion criteria, as only those patients 
with CGD who were ‘SRY negative’ prior to the study 
were enrolled. Since the SRY gene constitutes the primary 
candidate gene for this disorder (1), the likelihood of 
identifying the genetic etiology of gonadal dysgenesis 
among ‘SRY negative’ cases is lower. Furthermore, the 
subgroup with DGD was represented by cases with TRS, a 
condition in which environmental factors also play a role 
(34). Thus, although in some patients the genetic causes 
were identified in TRS (35, 36), the possible presence of 
non-genetic effects lowers the odds of a genetic diagnosis. 
In addition, although the published incidence of genomic 
rearrangements in DGD or sDSD patients varies between 
20 and 30% (3, 4, 5, 11), our current study did not identify 
any pathogenic CNV in these patients. These negative 
array-CGH results are likely due the limited number of 
cases assessed (n = 10). Finally, the full spectrum of the 
genetic determinants of DGD and sDSD is yet to be 
elucidated; thus, a genetic diagnosis can only be given for 
a minority of cases (1).
The sequencing of 37 DSD-related genes led to the 
identification of eight patients (23%) exhibiting oligogenic 
inheritance of more than one mutation in DSD genes, and 
this was not observed in controls (2.5%; P = 0.0003). This 
finding further reinforces recent studies demonstrating 
that oligogenicity is present in DSD patients and may 
at least partly explain the incomplete penetrance and 
variable expressivity within and across DSD families (6, 
7, 8). It is important to note, however, that our current 
study evaluated oligogenicity in only DSD genes, and 
did not include variants in known CHH genes. The fact 
that this strong association is present even when not 
including CHH genes (as previous studies have done (6, 
7)), coupled with a statistically equal number of CHH 
variants in both our DSD cohort and the CoLaus control 
population suggests a minimal or at best modifying role 
of CHH genes in the pathogenesis of DSD. Further, the 
role of CHH genes in DSD is debatable, given their distinct 
pathogenesis and endocrine profiles, as well as our results 
showing a nearly identical frequency of rare CHH variants 
in both DSD patients and CoLaus controls. However, 
larger genetic studies coupled with in vivo and/or in vitro 
functional studies will help to further clarify this.
In summary, the study clearly showed that an 
integrated approach is the best routine practice in the 
Confirmation of clinical
diagnosis  
n = 9
No variant
n = 15
Sequencing of 
DSD-related genes
n = 35 
Definitive genetic diagnosis
n = 12
Clinical diagnosis 
n = 23
At least one VUS
n = 8
Reclassification of clinical
diagnosis  
n = 3
Figure 3
Integrated approach in 46,XY DSD patients. DSD, disorders of sex development; VUS, variant of uncertain significance.
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diagnosis of 46,XY DSD. In those cases with a wide 
phenotype variability and reduced utility of conventional 
endocrine tests to fully determine the phenotype, reaching 
the definitive diagnosis may only be possible with parallel 
genetic testing. On the other hand, substantial prevalence 
of variants of uncertain significance or of possible 
oligogenic nature with different contribution to the 
phenotype underlay the importance of thorough clinical 
assessment. Therefore, in order to overcome potential 
obstacles in rendering an accurate diagnosis, data from 
clinical, biochemical and genetic assessment should be 
analyzed in an integrative manner. This approach should 
be then followed by reporting the data and comparing 
with other centers. Furthermore, only one third of 
patients harbor pathogenic mutations in DSD genes. The 
remaining patients argue for multi-national studies to 
identify additional genes involved in the pathogenesis 
of DSD.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
EC-18-0472.
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